Skip to Main Content

Author Details

Eliezer M Van Allen
Dana-Farber Cancer Institute
2009
239
81
PMIDPaper TitleJournal TitlePublished Year
38049664The role of APOBEC3B in lung tumor evolution and targeted cancer therapy resistance.Nat Genet2024
38049664The role of APOBEC3B in lung tumor evolution and targeted cancer therapy resistance.Nat Genet2024
36256912Randomized Trial of Olaparib With or Without Cediranib for Metastatic Castration-Resistant Prostate Cancer: The Results From National Cancer Institute 9984.J Clin Oncol2023
36256912Randomized Trial of Olaparib With or Without Cediranib for Metastatic Castration-Resistant Prostate Cancer: The Results From National Cancer Institute 9984.J Clin Oncol2023
36416812Disparities in the Inclusion of Racial and Ethnic Minority Groups and Older Adults in Prostate Cancer Clinical Trials: A Meta-analysis.JAMA Oncol2023
37658461Interplay of Mendelian and polygenic risk factors in Arab breast cancer patients.Genome Med2023
37653109Reply to: Addressing racial and ethnic disparities in AACR project GENIE.NPJ Precis Oncol2023
37729872Spatially aware deep learning reveals tumor heterogeneity patterns that encode distinct kidney cancer states.Cell Rep Med2023
37725576Integration of Genomic Sequencing Drives Therapeutic Targeting of PDGFRA in T-Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma.Clin Cancer Res2023
37572322Genome-guided discovery of cancer therapeutic targets.Cell Rep2023
37870965Genomic Tumor Correlates of Clinical Outcomes Following Organ-Sparing Chemoradiation Therapy for Bladder Cancer.Clin Cancer Res2023
36780008A Phase I Study of Combination Olaparib and Radium-223 in Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) with Bone Metastases (COMRADE).Mol Cancer Ther2023
37279009Circulating and Intratumoral Immune Determinants of Response to Atezolizumab plus Bevacizumab in Patients with Variant Histology or Sarcomatoid Renal Cell Carcinoma.Cancer Immunol Res2023
37085424Current Landscape of Genomic Biomarkers in Clear Cell Renal Cell Carcinoma.Eur Urol2023
36712083Integrative Analysis of Germline Rare Variants in Clear and Non-Clear Cell Renal Cell Carcinoma.medRxiv2023
36712053Spatially aware deep learning reveals tumor heterogeneity patterns that encode distinct kidney cancer states.bioRxiv2023
36951811Impact of an Expanded Definition of Family History on Outcomes of Active Surveillance for Prostate Cancer.J Urol2023
37121400Molecular markers of metastatic disease in KRAS-mutant lung adenocarcinoma.Ann Oncol2023
36862387First-line Systemic Treatment Options for Metastatic Castration-Sensitive Prostate Cancer: A Living Systematic Review and Network Meta-analysis.JAMA Oncol2023
36993558Analysis of evolutionary dynamics and clonal architecture in prostate cancer.bioRxiv2023
36862133Overcoming Barriers to Tumor Genomic Profiling through Direct-to-Patient Outreach.Clin Cancer Res2023
36658153Racial and ethnic disparities in a real-world precision oncology data registry.NPJ Precis Oncol2023
37658461Interplay of Mendelian and polygenic risk factors in Arab breast cancer patients.Genome Med2023
37653109Reply to: Addressing racial and ethnic disparities in AACR project GENIE.NPJ Precis Oncol2023
37729872Spatially aware deep learning reveals tumor heterogeneity patterns that encode distinct kidney cancer states.Cell Rep Med2023
37572322Genome-guided discovery of cancer therapeutic targets.Cell Rep2023
37725576Integration of Genomic Sequencing Drives Therapeutic Targeting of PDGFRA in T-Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma.Clin Cancer Res2023
37870965Genomic Tumor Correlates of Clinical Outcomes Following Organ-Sparing Chemoradiation Therapy for Bladder Cancer.Clin Cancer Res2023
36993558Analysis of evolutionary dynamics and clonal architecture in prostate cancer.bioRxiv2023
36951811Impact of an Expanded Definition of Family History on Outcomes of Active Surveillance for Prostate Cancer.J Urol2023
37121400Molecular markers of metastatic disease in KRAS-mutant lung adenocarcinoma.Ann Oncol2023
37085424Current Landscape of Genomic Biomarkers in Clear Cell Renal Cell Carcinoma.Eur Urol2023
37279009Circulating and Intratumoral Immune Determinants of Response to Atezolizumab plus Bevacizumab in Patients with Variant Histology or Sarcomatoid Renal Cell Carcinoma.Cancer Immunol Res2023
36780008A Phase I Study of Combination Olaparib and Radium-223 in Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) with Bone Metastases (COMRADE).Mol Cancer Ther2023
36712083Integrative Analysis of Germline Rare Variants in Clear and Non-Clear Cell Renal Cell Carcinoma.medRxiv2023
36712053Spatially aware deep learning reveals tumor heterogeneity patterns that encode distinct kidney cancer states.bioRxiv2023
36416812Disparities in the Inclusion of Racial and Ethnic Minority Groups and Older Adults in Prostate Cancer Clinical Trials: A Meta-analysis.JAMA Oncol2023
36862387First-line Systemic Treatment Options for Metastatic Castration-Sensitive Prostate Cancer: A Living Systematic Review and Network Meta-analysis.JAMA Oncol2023
36862133Overcoming Barriers to Tumor Genomic Profiling through Direct-to-Patient Outreach.Clin Cancer Res2023
36658153Racial and ethnic disparities in a real-world precision oncology data registry.NPJ Precis Oncol2023
34986355Integrative clinical and molecular characterization of translocation renal cell carcinoma.Cell Rep2022
36177448A patient-driven clinicogenomic partnership for metastatic prostate cancer.Cell Genom2022
35708671Association of High Tumor Mutation Burden in Non-Small Cell Lung Cancers With Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1 Blockade Across PD-L1 Expression Levels.JAMA Oncol2022
36103646Addition of Germline Testing to Tumor-Only Sequencing Improves Detection of Pathogenic Germline Variants in Men With Advanced Prostate Cancer.JCO Precis Oncol2022
35512711Germline predisposition to pediatric Ewing sarcoma is characterized by inherited pathogenic variants in DNA damage repair genes.Am J Hum Genet2022
35389777Genome-wide analysis of somatic noncoding mutation patterns in cancer.Science2022
35446942Insights into Immune Escape During Tumor Evolution and Response to Immunotherapy Using a Rat Model of Breast Cancer.Cancer Immunol Res2022
35945087Reply to Yuxuan Song, Yiqing Du, and Tao Xu's Letter to the Editor re: Matthew Mossanen, Filipe L.F. Carvalho, Vinayak Muralidhar, et al. Genomic Features of Muscle-invasive Bladder Cancer Arising After Prostate Radiotherapy. Eur Urol 2022;81:466-73.Eur Urol2022
35943799Patterns of structural variation define prostate cancer across disease states.JCI Insight2022
36075011Mutational Footprint of Platinum Chemotherapy in a Secondary Thyroid Cancer.JCO Precis Oncol2022
  • 1 - 50 of 478

Recommended Authors

Job van Riet
Erasmus MC Cancer Institute
Career Start Year 2017
Number of shared co-authors 3
Rohan Bareja
Case Western Reserve University
Career Start Year 2017
Number of shared co-authors 35
Sebastian Uhrig
National Center for Tumor Diseases (NCT), German Cancer Research Center (DKFZ)
Career Start Year 2016
Number of shared co-authors 5
Zachary L Skidmore
Washington University in St. Louis School of Medicine
Career Start Year 2015
Number of shared co-authors 17
Sahil Seth
The University of Texas MD Anderson Cancer Center
Career Start Year 2014
Number of shared co-authors 46
Katie M Campbell
McDonnell Genome Institute, Washington University School of Medicine
Career Start Year 2014
Number of shared co-authors 13
Daniel H Hovelson
Michigan Center for Translational Pathology, University of Michigan ann arbor
Career Start Year 2014
Number of shared co-authors 33
Arshi Arora
Memorial Sloan Kettering Cancer Center
Career Start Year 2011
Number of shared co-authors 28
Matti Annala
University of British Columbia
Career Start Year 2011
Number of shared co-authors 28
Gunes Gundem
Memorial Sloan Kettering Cancer Center
Career Start Year 2010
Number of shared co-authors 19
Joshua F McMichael
Washington University
Career Start Year 2009
Number of shared co-authors 39
Oscar Krijgsman
The Netherlands Cancer Institute
Career Start Year 2008
Number of shared co-authors 5
Alexander W Wyatt
University of British Columbia
Career Start Year 2007
Number of shared co-authors 48
Nicola Waddell
QIMR Berghofer Medical Research Institute
Career Start Year 2006
Number of shared co-authors 14
Linghua Wang
The University of Texas M. D. Anderson
Career Start Year 2006
Number of shared co-authors 34
Albrecht Stenzinger
Institute of Pathology, University Hospital Heidelberg
Career Start Year 2005
Number of shared co-authors 29
Jamie K Teer
H. Lee Moffitt Cancer Center and Research Institute
Career Start Year 2005
Number of shared co-authors 7
Jianhua Zhang
University of Texas MD Anderson Cancer Center
Career Start Year 2003
Number of shared co-authors 51
Trevor J Pugh
Princess Margaret Cancer Centre, University Health Network
Career Start Year 2003
Number of shared co-authors 77
Sherri Z Millis
Foundation Medicine Inc
Career Start Year 2003
Number of shared co-authors 10
Obi L Griffith
Washington University
Career Start Year 2003
Number of shared co-authors 36
Olivier Harismendy
University of California
Career Start Year 2003
Number of shared co-authors 8
Peter Horak
German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT)
Career Start Year 2003
Number of shared co-authors 19
Malachi Griffith
Washington University
Career Start Year 2003
Number of shared co-authors 39
Fengshen Kuo
Memorial Sloan Kettering Cancer Center
Career Start Year 2003
Number of shared co-authors 14
Simon Kreutzfeldt
German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT)
Career Start Year 2002
Number of shared co-authors 15
Volker Endris
Institute of Pathology, University Hospital Heidelberg
Career Start Year 2001
Number of shared co-authors 5
Richard B Schwab
Department of Medicine and Moores Cancer Center, University of California San Diego
Career Start Year 2000
Number of shared co-authors 3
Kenna R Mills Shaw
The University of Texas MD Anderson Cancer Center
Career Start Year 1999
Number of shared co-authors 54
Martijn P Lolkema
Erasmus MC Cancer Institute
Career Start Year 1999
Number of shared co-authors 17

Collaborators

Levi A Garraway
Broad Institute of Harvard and MIT
Co-authored papers 59
Toni K Choueiri
Dana-Farber Cancer Institute
Co-authored papers 44
Gad Getz
Broad Institute of the Massachusetts Institute of Technology and Harvard
Co-authored papers 37
Nikhil Wagle
Dana-Farber Cancer Institute
Co-authored papers 27
Mary-Ellen Taplin
Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute
Co-authored papers 25
Scott L Carter
Co-authored papers 21
Stacey Gabriel
Broad Institute of MIT and Harvard
Co-authored papers 19
Stephanie A Wankowicz
University of California San Francisco
Co-authored papers 19
Peter S Nelson
Fred Hutchinson Cancer Center
Co-authored papers 18
Amaro Taylor-Weiner
Co-authored papers 17
Pasi A J??nne
Dana-Farber Cancer Institute
Co-authored papers 16
Jihye Park
Dana-Farber Cancer Institute, Harvard Medical School
Co-authored papers 15
Philip W Kantoff
Memorial Sloan Kettering Cancer Center
Co-authored papers 13
Jake Conway
Co-authored papers 13
Nikolaus Schultz
Memorial Sloan Kettering Cancer Center
Co-authored papers 13
Catherine J Wu
Co-authored papers 12
Mara Rosenberg
Broad Institute of MIT and Harvard
Co-authored papers 12
Michael S Lawrence
Co-authored papers 12
Mark A Rubin
University of Bern
Co-authored papers 12
Jaegil Kim
Co-authored papers 11
Eric S Lander
Vanderbilt-Ingram Cancer Center, Vanderbilt University
Co-authored papers 11
Massimo Loda
Weill Medical College of Cornell University
Co-authored papers 11
Himisha Beltran
Dana-Farber Cancer Institute
Co-authored papers 11
Colin C Pritchard
University of Washington, USA Brotman Baty Institute for Precision Medicine
Co-authored papers 11
Bruce Montgomery
Fred Hutchinson Cancer Center, University of Washington
Co-authored papers 11
Matthew Meyerson
Broad Institute
Co-authored papers 10
Arul M Chinnaiyan
University of Michigan Medical School.
Co-authored papers 10
Stacy W Gray
City of Hope Comprehensive Cancer Center
Co-authored papers 10
Wassim Abida
Memorial Sloan Kettering Cancer Center
Co-authored papers 10
William C Hahn
Broad Institute of MIT and Harvard, USA Dana-Farber Cancer Institute
Co-authored papers 10
Release 1.2